{"symbol": "NTLA", "companyName": "Intellia Therapeutics Inc", "exchange": "NASDAQ/NMS (GLOBAL MARKET)", "industry": "Pharmaceutical Preparation Manufacturing ", "website": "www.intelliatx.com", "description": "Intellia Therapeutics is a leading clinical-stage genome editing company, focused on the development of proprietary, potentially curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creating enhanced engineered cells that can treat oncological and immunological diseases. Intellia's combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts it in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create new classes of therapeutic products.", "CEO": "John Leonard", "securityName": "Intellia Therapeutics Inc", "issueType": "cs", "sector": "Manufacturing", "primarySicCode": 2835, "employees": 312, "tags": ["Health Technology", "Biotechnology", "Manufacturing", "Pharmaceutical Preparation Manufacturing "], "address": "40 Erie St Ste 130", "address2": null, "state": "Massachusetts", "city": "Cambridge", "zip": "02139-4254", "country": "US", "phone": "18572856200"}